ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1912

Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort
Abstract Number: 1913

Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration
Abstract Number: 1914

Performance Comparison of Artificial Intelligence tools ChatGPT, Bing AI, and Google Bard for Clinical Rheumatology Decision Support: When AI Talks Rheumatology
Abstract Number: 1915

Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence
Abstract Number: 1916

Adherence to cervical cancer screening programs in women with Systemic Lupus Erythematosus
Abstract Number: 1917

Characterizing the Frequency and Timing of Changes in Patient-Reported Social Risk Factors among Rheumatology Outpatients
Abstract Number: 1918

Vigorous Physical Activity in Patients with SLE Was Not Associated with Disease Activity or Socioeconomic and Social Factors
Abstract Number: 1919

Financial insecurity and discrimination are associated with patient-reported quality of life in patients with SLE
Abstract Number: 1920

Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Abstract Number: 1921

Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
Abstract Number: 1922

Exploration of patient and clinician perspectives on rehabilitation in contemporary rheumatology care for rheumatoid arthritis: A qualitative study
Abstract Number: 1923

A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
Abstract Number: 1924

Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
Abstract Number: 1925

Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Abstract Number: 1926

Real World Rate of Efficacy of Adalimumab Biosimilars Following a Mandated Switch in an Academic Medical Center

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].